We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Circulating Tumor Cell-Based AR-V7 Test Validated

By LabMedica International staff writers
Posted on 12 Jul 2018
Print article
Image: The AR-V7 protein is a prognostic and predictive biomarker. Detection of AR-V7-positive tumor cells by the Oncotype DX test indicates that the patient will no longer benefit from commonly prescribed ARSI therapies but can still benefit from chemotherapy to prolong survival (Photo courtesy of Genomic Health/Epic Sciences).
Image: The AR-V7 protein is a prognostic and predictive biomarker. Detection of AR-V7-positive tumor cells by the Oncotype DX test indicates that the patient will no longer benefit from commonly prescribed ARSI therapies but can still benefit from chemotherapy to prolong survival (Photo courtesy of Genomic Health/Epic Sciences).
A blood test to determine whether to treat patients with metastatic castration-resistant prostate cancer (mCRPC) with an androgen receptor signaling inhibitor (ARSI) or taxane is an unmet medical need.

Several diverse resistance mechanisms to ARS inhibitors have been identified through molecular profiling, many of which have been further elucidated to varying degrees in preclinical model systems. Androgen receptor splice variant 7 (AR-V7) is an alternatively spliced isoform of the AR gene that contains the DNA-binding domain but lacks the regulatory ligand-binding domain, leading to constitutive activation of oncogenic signaling and cell proliferation.

An international team of scientists collaborating with the Memorial Sloan Kettering Cancer Center, New York, NY, USA) obtained blood samples from 248 patients with histologically confirmed mCRPC who were undergoing a change in systemic therapy for progressive disease. The team only analyzed 142 blood samples (70 before initiation of therapy with an ARS inhibitor; 72 before initiation of therapy with a taxane) for the utility analysis in the second-line or greater therapy setting.

Laboratory studies included complete blood count, chemistry panel (albumin, alkaline phosphatase, lactate dehydrogenase, prostate-specific antigen (PSA), and hemoglobin levels), and serum testosterone levels to confirm castration status (<50 ng/dL). Slides created from blood samples from patients with mCRPC underwent automated immunofluorescent staining for DNA, cytokeratins, CD45, and AR-V7. Fluorescent scanners and morphologic algorithms were used for identification of circulating tumor cells (CTCs), evaluating two slides per blood sample. Blood samples with at least one CTC with an intact nucleus and nuclear-localized AR-V7 signal to noise ratio above a previously established and validated background intensity per two slides tested ( ~ 1 mL of blood) were scored as AR-V7 positive. Blood samples without AR-V7–positive CTCs, or with no CTCs detected, were scored as AR-V7 negative.

The team found that among the 142 patients in the study (mean ± SD age, 69.5 ± 9.6 years), 70 were designated as high risk by conventional prognostic factors. In this high-risk group, patients positive for AR-V7 who were treated with taxanes had superior overall survival relative to those treated with ARS inhibitors (median overall survival, 14.3 versus 7.3 months). Patients negative for AR-V7 who were treated with ARS inhibitors had superior overall survival relative to those treated with taxanes (median overall survival, 19.8 versus 12.8 months). The AR-V7 test is offered by Epic Sciences (San Diego, CA, USA).

Howard I. Scher, MD, a Medical Oncologist and lead author of the study said, “During the treatment of metastatic prostate cancer, physicians will now be able to use AR-V7 status to determine when a patient’s cancer has become resistant to androgen receptor-directed therapy and will respond better to chemotherapy, enabling the patient to live longer.”

The authors concluded that studies must correlate response to treatment with assay positivity, and not just survival data, to ensure that the assay is not simply a prognostic biomarker. AR-V7 positivity, in this study, is associated with higher lactate dehydrogenase, alkaline phosphatase, and PSA levels, suggesting a higher disease burden in the taxane arm. This finding indicates that AR-V7 positivity by this assay may be more prognostic, associated with disease burden, than predictive.” The study was published on June 28, 2018, in the journal JAMA Oncology.

Related Links:
Memorial Sloan Kettering Cancer Center
Epic Sciences
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.